stomach cancer

Amgen
Biotech

Amgen halts gastric cancer trial after subpar efficacy analysis

Fortitude-102 was testing bemarituzumab, a monoclonal antibody, in combination with chemotherapy and BMS’ Opdivo in 515 patients.
Darren Incorvaia Nov 5, 2025 4:35am
Close up shot of the target from a dart game

Ono's BMS-partnered IO drug passes phase 2 gastric cancer test

Oct 9, 2025 10:10am
Graphic of a one dollar bill with nuts and bolts scattered across it

Bolt halves workforce again to find cash for cancer drug readout

Oct 2, 2025 6:45am
downturn economy markets bank negative fall down

Amgen-Zai stomach cancer asset loses OS benefit in final analysis

Sep 3, 2025 4:33pm
MA

I-Mab buys Bridge Health for $3M to strengthen givastomig push

Jul 17, 2025 8:45am
Close up shot of the target from a dart game

Amgen, Zai say stomach cancer candidate hits phase 3 mark

Jun 30, 2025 10:36am